In a subgroup analysis of patients with a history of prior MDS/MPN (n = 40), those with mutant RUNX1 had significantly shorter EFS compared with wild-type RUNX1 (1.35 vs. 6.34 months; p = 0.012) (Figure 5) and trend to inferior OS (p = 0.079) in the older patient cohort. Here, RUNX1 is linked to myeloproliferative neoplasm.